Anti-GM-CSF monotherapy was slightly effective in ovarian cancers, and the combination of anti-GM-CSF antibody with anti-VEGF antibody was found to be highly effective in this study (Fig. 6a, b). Here, CSF2 is linked to ovarian carcinoma.